Amylyx Pharmaceuticals, Inc. (AMLX)
NMS · Healthcare · Drug Manufacturers - Specialty & Generic
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | |
| Operating Income | (36.0M) | (36.6M) | (43.8M) | (45.7M) |
| Net Income | (34.4M) | (33.0M) | (41.3M) | (43.4M) |
| Diluted EPS | $-0.37 | $-0.30 | $-0.37 | $-0.39 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 22.2M | 380.8M | 87.4M | 0.00 |
| Gross Profit | 19.2M | 355.3M | (37.3M) | 0.00 |
| Operating Income | (201.3M) | 38.8M | (255.7M) | (153.3M) |
| Net Income | (198.4M) | 49.3M | (301.7M) | (144.7M) |
| Diluted EPS | $-3.39 | $0.70 | $-4.43 | N/A |